279 related articles for article (PubMed ID: 26062443)
1. Genomic characterization of a large panel of patient-derived hepatocellular carcinoma xenograft tumor models for preclinical development.
Gu Q; Zhang B; Sun H; Xu Q; Tan Y; Wang G; Luo Q; Xu W; Yang S; Li J; Fu J; Chen L; Yuan S; Liang G; Ji Q; Chen SH; Chan CC; Zhou W; Xu X; Wang H; Fang DD
Oncotarget; 2015 Aug; 6(24):20160-76. PubMed ID: 26062443
[TBL] [Abstract][Full Text] [Related]
2. Establishment of a hepatocellular carcinoma patient-derived xenograft platform and its application in biomarker identification.
Hu B; Li H; Guo W; Sun YF; Zhang X; Tang WG; Yang LX; Xu Y; Tang XY; Ding GH; Qiu SJ; Zhou J; Li YX; Fan J; Yang XR
Int J Cancer; 2020 Mar; 146(6):1606-1617. PubMed ID: 31310010
[TBL] [Abstract][Full Text] [Related]
3. Establishment and Preclinical Therapy of Patient-derived Hepatocellular Carcinoma Xenograft Model.
Wu Y; Wang J; Zheng X; Chen Y; Huang M; Huang Q; Xiao W; Wei H; Tian Z; Sun R; Sun C
Immunol Lett; 2020 Jul; 223():33-43. PubMed ID: 32335145
[TBL] [Abstract][Full Text] [Related]
4. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.
Joshi JJ; Coffey H; Corcoran E; Tsai J; Huang CL; Ichikawa K; Prajapati S; Hao MH; Bailey S; Wu J; Rimkunas V; Karr C; Subramanian V; Kumar P; MacKenzie C; Hurley R; Satoh T; Yu K; Park E; Rioux N; Kim A; Lai WG; Yu L; Zhu P; Buonamici S; Larsen N; Fekkes P; Wang J; Warmuth M; Reynolds DJ; Smith PG; Selvaraj A
Cancer Res; 2017 Dec; 77(24):6999-7013. PubMed ID: 29247039
[TBL] [Abstract][Full Text] [Related]
5. Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity.
Chen X; Shen C; Wei Z; Zhang R; Wang Y; Jiang L; Chen K; Qiu S; Zhang Y; Zhang T; Chen B; Xu Y; Feng Q; Huang J; Zhong Z; Li H; Che G; Xiao K
Cancer Biol Med; 2021 Feb; 18(1):184-198. PubMed ID: 33628593
[TBL] [Abstract][Full Text] [Related]
6. Predicting HCC Response to Multikinase Inhibitors With In Vivo Cirrhotic Mouse Model for Personalized Therapy.
Huang DQ; Muthiah MD; Zhou L; Jumat H; Tan WX; Lee GH; Lim SG; Kow A; Bonney G; Shridhar I; Lim YT; Wee A; Pang YH; Soon G; Chow P; Dan YY
Cell Mol Gastroenterol Hepatol; 2021; 11(5):1313-1325. PubMed ID: 33340714
[TBL] [Abstract][Full Text] [Related]
7. OGDHL silencing promotes hepatocellular carcinoma by reprogramming glutamine metabolism.
Dai W; Xu L; Yu X; Zhang G; Guo H; Liu H; Song G; Weng S; Dong L; Zhu J; Liu T; Guo C; Shen X
J Hepatol; 2020 May; 72(5):909-923. PubMed ID: 31899205
[TBL] [Abstract][Full Text] [Related]
8. CRIPTO promotes an aggressive tumour phenotype and resistance to treatment in hepatocellular carcinoma.
Karkampouna S; van der Helm D; Gray PC; Chen L; Klima I; Grosjean J; Burgmans MC; Farina-Sarasqueta A; Snaar-Jagalska EB; Stroka DM; Terracciano L; van Hoek B; Schaapherder AF; Osanto S; Thalmann GN; Verspaget HW; Coenraad MJ; Kruithof-de Julio M
J Pathol; 2018 Jul; 245(3):297-310. PubMed ID: 29604056
[TBL] [Abstract][Full Text] [Related]
9. Generation of matched patient-derived xenograft in vitro-in vivo models using 3D macroporous hydrogels for the study of liver cancer.
Fong ELS; Toh TB; Lin QXX; Liu Z; Hooi L; Mohd Abdul Rashid MB; Benoukraf T; Chow EK; Huynh TH; Yu H
Biomaterials; 2018 Mar; 159():229-240. PubMed ID: 29353739
[TBL] [Abstract][Full Text] [Related]
10. Characterization of copy number alterations in a mouse model of fibrosis-associated hepatocellular carcinoma reveals concordance with human disease.
Chappell G; Silva GO; Uehara T; Pogribny IP; Rusyn I
Cancer Med; 2016 Mar; 5(3):574-85. PubMed ID: 26778414
[TBL] [Abstract][Full Text] [Related]
11. Microarray profiling shows distinct differences between primary tumors and commonly used preclinical models in hepatocellular carcinoma.
Wang W; Iyer NG; Tay HT; Wu Y; Lim TK; Zheng L; Song IC; Kwoh CK; Huynh H; Tan PO; Chow PK
BMC Cancer; 2015 Oct; 15():828. PubMed ID: 26520397
[TBL] [Abstract][Full Text] [Related]
12. Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts.
Xin H; Wang K; Hu G; Xie F; Ouyang K; Tang X; Wang M; Wen D; Zhu Y; Qin X
PLoS One; 2014; 9(1):e85308. PubMed ID: 24416385
[TBL] [Abstract][Full Text] [Related]
13. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1-3 signaling, but not FGFR4 signaling.
Shigesawa T; Maehara O; Suda G; Natsuizaka M; Kimura M; Shimazaki T; Yamamoto K; Yamada R; Kitagataya T; Nakamura A; Suzuki K; Ohara M; Kawagishi N; Umemura M; Nakai M; Sho T; Morikawa K; Ogawa K; Ohnishi S; Sugiyama M; Mizokami M; Takeda H; Sakamoto N
Carcinogenesis; 2021 Feb; 42(1):58-69. PubMed ID: 32449510
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive comparison of patient-derived xenograft models in Hepatocellular Carcinoma and metastatic Liver Cancer.
Xu W; Zhao ZY; An QM; Dong B; Lv A; Li CP; Guan XY; Tian XY; Wu JH; Hao CY
Int J Med Sci; 2020; 17(18):3073-3081. PubMed ID: 33173428
[TBL] [Abstract][Full Text] [Related]
15. Rational drug combination design in patient-derived avatars reveals effective inhibition of hepatocellular carcinoma with proteasome and CDK inhibitors.
Lim JJ; Hooi L; Dan YY; Bonney GK; Zhou L; Chow PK; Chee CE; Toh TB; Chow EK
J Exp Clin Cancer Res; 2022 Aug; 41(1):249. PubMed ID: 35971164
[TBL] [Abstract][Full Text] [Related]
16. Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.
Woo XY; Giordano J; Srivastava A; Zhao ZM; Lloyd MW; de Bruijn R; Suh YS; Patidar R; Chen L; Scherer S; Bailey MH; Yang CH; Cortes-Sanchez E; Xi Y; Wang J; Wickramasinghe J; Kossenkov AV; Rebecca VW; Sun H; Mashl RJ; Davies SR; Jeon R; Frech C; Randjelovic J; Rosains J; Galimi F; Bertotti A; Lafferty A; O'Farrell AC; Modave E; Lambrechts D; Ter Brugge P; Serra V; Marangoni E; El Botty R; Kim H; Kim JI; Yang HK; Lee C; Dean DA; Davis-Dusenbery B; Evrard YA; Doroshow JH; Welm AL; Welm BE; Lewis MT; Fang B; Roth JA; Meric-Bernstam F; Herlyn M; Davies MA; Ding L; Li S; Govindan R; Isella C; Moscow JA; Trusolino L; Byrne AT; Jonkers J; Bult CJ; Medico E; Chuang JH; ;
Nat Genet; 2021 Jan; 53(1):86-99. PubMed ID: 33414553
[TBL] [Abstract][Full Text] [Related]
17. Establishment of a Patient-Derived Xenograft Tumor From Hepatitis C-Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy.
Nazzal M; Sur S; Steele R; Khatun M; Patra T; Phillips N; Long J; Ray R; Ray RB
Hepatology; 2020 Aug; 72(2):379-388. PubMed ID: 32356575
[TBL] [Abstract][Full Text] [Related]
18. Uncovering Biological Factors That Regulate Hepatocellular Carcinoma Growth Using Patient-Derived Xenograft Assays.
Zhu M; Li L; Lu T; Yoo H; Zhu J; Gopal P; Wang SC; Porembka MR; Rich NE; Kagan S; Odewole M; Renteria V; Waljee AK; Wang T; Singal AG; Yopp AC; Zhu H
Hepatology; 2020 Sep; 72(3):1085-1101. PubMed ID: 31899548
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib induces death of human hepatocellular carcinoma cells harboring an activated FGF signaling pathway through inhibition of FGFR-MAPK cascades.
Hoshi T; Watanabe Miyano S; Watanabe H; Sonobe RMK; Seki Y; Ohta E; Nomoto K; Matsui J; Funahashi Y
Biochem Biophys Res Commun; 2019 May; 513(1):1-7. PubMed ID: 30944079
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of vascular endothelial growth factor inhibitor sunitinib in preclinical models of hepatocellular carcinoma.
Bagi CM; Gebhard DF; Andresen CJ
Eur J Gastroenterol Hepatol; 2012 May; 24(5):563-74. PubMed ID: 22314934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
